CL2009000405A1 - Compuestos derivados de pirrolo [2,3 b] pirazina, inhibidores jak y cyk; y sus usos en el tratamiento de enfermedades inflamatorias, autoinmune y cancer. - Google Patents
Compuestos derivados de pirrolo [2,3 b] pirazina, inhibidores jak y cyk; y sus usos en el tratamiento de enfermedades inflamatorias, autoinmune y cancer.Info
- Publication number
- CL2009000405A1 CL2009000405A1 CL2009000405A CL2009000405A CL2009000405A1 CL 2009000405 A1 CL2009000405 A1 CL 2009000405A1 CL 2009000405 A CL2009000405 A CL 2009000405A CL 2009000405 A CL2009000405 A CL 2009000405A CL 2009000405 A1 CL2009000405 A1 CL 2009000405A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- pyrrolo
- autoimmune
- cyk
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Abstract
Compuestos derivados de pirrolo [2,3 b] pirazinas sustituidas; y su uso en la enfermedad autoinmune, trastornos inflamatorios, trastornos proliferativos, cáncer, mediados por la inhibición de jak y syk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3103508P | 2008-02-25 | 2008-02-25 | |
US14651409P | 2009-01-22 | 2009-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000405A1 true CL2009000405A1 (es) | 2010-02-26 |
Family
ID=40514045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000405A CL2009000405A1 (es) | 2008-02-25 | 2009-02-23 | Compuestos derivados de pirrolo [2,3 b] pirazina, inhibidores jak y cyk; y sus usos en el tratamiento de enfermedades inflamatorias, autoinmune y cancer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8119636B2 (es) |
EP (1) | EP2247593B1 (es) |
JP (1) | JP5284377B2 (es) |
KR (1) | KR20100114095A (es) |
CN (1) | CN101952296B (es) |
AR (1) | AR070467A1 (es) |
AT (1) | ATE519763T1 (es) |
AU (1) | AU2009218609A1 (es) |
BR (1) | BRPI0907928A2 (es) |
CA (1) | CA2713718A1 (es) |
CL (1) | CL2009000405A1 (es) |
IL (1) | IL206818A0 (es) |
MX (1) | MX2010009023A (es) |
PE (1) | PE20091738A1 (es) |
RU (1) | RU2010139284A (es) |
TW (1) | TW200942543A (es) |
WO (1) | WO2009106444A1 (es) |
ZA (1) | ZA201004942B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009106445A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
EP2250172B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
PT3354650T (pt) | 2008-12-19 | 2022-06-20 | Vertex Pharma | Compostos úteis como inibidores da cinase atr |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
EP2571881A1 (en) | 2010-05-20 | 2013-03-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
KR20130083386A (ko) * | 2010-05-20 | 2013-07-22 | 에프. 호프만-라 로슈 아게 | 피롤로[2,3-b]피라진-7-카복스아마이드 유도체 및 JAK 및 SYK 억제제로서의 그의 용도 |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
BR112014004569A2 (pt) * | 2011-09-01 | 2017-06-13 | F. Hoffmann-La Roche Ag | composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
IN2014CN02501A (es) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013064445A1 (en) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN104159891B (zh) | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
KR20150043323A (ko) * | 2012-08-21 | 2015-04-22 | 에프. 호프만-라 로슈 아게 | 비장 티로신 키나제 억제제로서 피롤로[2,3-b]피라진 |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
US9403780B2 (en) | 2013-05-14 | 2016-08-02 | 3M Innovative Properties Company | Pyridine- or pyrazine-containing compounds |
JP6543252B2 (ja) | 2013-12-06 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体 |
MX2016015874A (es) | 2014-06-05 | 2017-03-27 | Vertex Pharma | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
EP4077316A1 (en) | 2019-12-20 | 2022-10-26 | Pfizer Inc. | Benzimidazole derivatives |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2699568C (en) | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
JP2005534618A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | 神経変性疾患用の、c−junn−末端キナーゼ阻害剤としての7−アザインドール |
CA2550361C (en) * | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
EP1814883A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
PT2247592E (pt) * | 2008-02-25 | 2011-11-03 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
EP2250172B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
-
2009
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Application Discontinuation
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en active Application Filing
- 2009-02-16 EP EP09714560A patent/EP2247593B1/en not_active Not-in-force
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
-
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0907928A2 (pt) | 2015-07-28 |
ZA201004942B (en) | 2011-12-28 |
EP2247593A1 (en) | 2010-11-10 |
AR070467A1 (es) | 2010-04-07 |
KR20100114095A (ko) | 2010-10-22 |
TW200942543A (en) | 2009-10-16 |
JP2011513263A (ja) | 2011-04-28 |
CA2713718A1 (en) | 2009-09-03 |
MX2010009023A (es) | 2010-09-07 |
ATE519763T1 (de) | 2011-08-15 |
CN101952296B (zh) | 2013-08-21 |
PE20091738A1 (es) | 2009-11-13 |
US8119636B2 (en) | 2012-02-21 |
RU2010139284A (ru) | 2012-04-10 |
IL206818A0 (en) | 2010-12-30 |
CN101952296A (zh) | 2011-01-19 |
US20090215785A1 (en) | 2009-08-27 |
JP5284377B2 (ja) | 2013-09-11 |
WO2009106444A1 (en) | 2009-09-03 |
EP2247593B1 (en) | 2011-08-10 |
AU2009218609A1 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000405A1 (es) | Compuestos derivados de pirrolo [2,3 b] pirazina, inhibidores jak y cyk; y sus usos en el tratamiento de enfermedades inflamatorias, autoinmune y cancer. | |
CL2009000406A1 (es) | Compuestos derivados de pirrolo[2,3-b]pirazinas; y su uso en la enfermedad autoinmune, trastornos inflamatorios, trastornos proliferativos, cancer, mediados por inhibidores selectivos de la jak 3. | |
CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
CL2008001709A1 (es) | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. | |
CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
CY1122368T1 (el) | Παραγωγα 3-οξο-2,3,5,8-τετραϋδρο-[1,2,4]τριαζολο[4,3-α]πυριμιδινης για την αγωγη αναπνευστικων νοσων | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
CL2012001073A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias. | |
MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
UY30892A1 (es) | Inhibidores de la actividad akt | |
CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
ECSP11011534A (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak | |
ECSP088425A (es) | INHIBIDORES DE LA ACTIVIDAD Akt | |
CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. |